Update from Rejuvenation Biotech – FDA April 7, 2017August 21, 2014 by Justin Padinske LIVE UPDATE James O’Neill (Mithril Capital) on the FDA – The people there like science and curing disease. It is not a people problem, the FDA is structured to make it difficult to move trials forward. Justin Padinske
